Moleculin Biotech MBRX 深 沪
等待开盘 08-31 09:30:00 美东时间
0.6499
-0.039
-5.63%
华盛通- 最 高0.709
- 今 开0.69
- 成交量 61.43万股
- 最 低 0.64
- 昨 收 0.6887
- 总市值 1.27万
- 52周最高 15.75
- 市盈率 静 --
- 换手率 3153.88%
- 52周最低 0.1614
- 委 比 81.49%
- 总股本 1.95万
- 历史最高 21555.00
- 量 比 0.86
- 振 幅 10.02%
- 历史最低 0.1614
- 每 手 1
- 风险率 3.92%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅768.26%！Ascendiant Capital维持RenovoRx(RNXT)"买入"评级，目标价上调至14.5美元
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从14美元升至14.5美元；HC Wainwright & Co.：维持Generate Biomedicines"买入"评级，目标价从25美元升至30美元
今天 18:14
HC Wainwright & Co. Maintains Buy on Moleculin Biotech, Lowers Price Target to $3
HC Wainwright & Co. analyst Sara Nik maintains Moleculin Biotech (NASDAQ:MBRX) with a Buy and lowers the price target from $22 to $3.
08-28 19:10
Moleculin CEO, Walter Klemp, Participates in the Virtual Investor “Why Now” On-Demand Conference
Moleculin Biotech, Inc. participated in the Virtual Investor “Why Now” on-demand conference, highlighting its clinical progress and long-term opportunity. Walter Klemp, CEO, discussed encouraging interim results from the pivotal Phase 2/3 MIRACLE trial evaluating Annamycin for relapsed or refractory acute myeloid leukemia (AML). The presentation emphasized Annamycin's differentiated clinical profile, enrollment progress, commercial opportunity, a...
08-27 13:01
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share from the same period last year.
08-14 20:48
Moleculin Biotech completes $9.3M equity financing
Moleculin Biotech ( ($MBRX) ) has shared an announcement. On July 31, 2026, Mol...
08-04 06:22
Moleculin Announces Pricing of $9.3 Million Public Offering
Moleculin Biotech announced a public offering of 12.4 million shares and warrants for up to 37.1 million shares at $0.75 per share, expected to close on August 3. Proceeds will fund the clinical development of Annamycin and working capital. Roth Capital Partners is the placement agent, and Maxim Group is the financial advisor. Annamycin is in Phase 3 for relapsed/refractory acute myeloid leukemia and soft tissue sarcoma.
07-31 14:12
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
Moleculin Biotech shares are trading lower. The company announced a best‑efforts public offering of stock and warrants, including pre‑funded options to cap ownership.
07-30 02:57
Why is Moleculin Stock Falling Today?
Moleculin Biotech Inc. (NASDAQ:MBRX) stock is trading lower on Tuesday after the company shared preliminary efficacy data from the first 45 patients enrolled in Part A of its pivotal Phase 2/3 MIRACLE trial that did not reach statistical significance. However, the company noted that both Annamycin t...
07-01 02:00
Moleculin Biotech Announces Its Data From Phase 2/3 MIRACLE Study For Both Annamycin Treatment Arms Shows Efficacy; Composite Complete Remission Reaches 50%, 57% In Respective Arms
Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), today announced positive preliminary unblinded efficacy results from the first 45 patients enrolled in Part A of the Company's pivotal Phase 2/3 MIRACLE trial, analyzed on a full intent-to-treat basis with no patient exclusions....
06-30 20:34
